New primary monoclonal antibodies
New primary monoclonal antibodies · 19. September 2023
SYnabs monoclonal antibodies to metalloproteinases proMMP9 and activated MMP9 as diagnostic and therapeutic tools for immune diseases, neurological diseases and strokes
New primary monoclonal antibodies · 24. April 2023
CRP is synthesized by the liver in response to several inflammatory cytokines and is a well-established biomarker of inflammation and infection. Elevated CRP levels are associated with several diseases, including inflammatory bowel disease, rheumatoid arthritis, cardiovascular disease, infection, and cancer. SYnAbs Monoclonal antibodies offer several advantages for CRP diagnosis in a precision medicine context.
New primary monoclonal antibodies · 11. February 2023
Thanks to unique technologies to break immune tolerance, SYnAbs generate monoclonal antibodies to Matrix metalloproteinases (MMPs), extracellular proteinase enzymes involved in the degradation of the extracellular matrix.
New primary monoclonal antibodies · 25. November 2022
Synabs announces a large Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins
New primary monoclonal antibodies · 03. October 2022
SYnAbs monoclonals specific to glucagon without cross-reaction to GLP-1, Glicentin, Oxyntomodulin and Proglucagon, to diagnose diabetes and glucagonomas diseases
New primary monoclonal antibodies · 13. January 2022
SYnAbs unique monoclonal antibodies are highly specific to hemoglobin mutations HbA, HbC, HbE, HbS, and pan-Hb to detect sickle cell disease.
New primary monoclonal antibodies · 30. October 2021
Benefit from natural in-vivo maturation to get access to highly specific and high affinity rat monoclonal antibodies for therapeutic use targeting transmembrane proteins GPCR, ion channels and other complex epitopes
New primary monoclonal antibodies · 26. October 2020
SYnAbs has developed R&D and therapeutic IL-1β monoclonal antibodies to diagnose and treat auto-inflammatory diseases and cancer in combo with immune checkpoint inhibitors
New primary monoclonal antibodies · 24. October 2020
SYnabs develops surrogate antibodies for preclinical evaluation of therapeutic antibody candidates in mouse, rat, and guinea pig species.
New primary monoclonal antibodies · 28. September 2020
Synabs unique anti-KIAA1199, anti-CEMIP, anti-Hybid monoclonal antibody
SYnAbs S.A.
Rue Auguste Piccard, 48
I-Tech Incubator 2
B-6041 Gosselies
Belgium
+32 (0)71/374.880
BE 0637.716.206
